These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
135 related articles for article (PubMed ID: 12161027)
1. LF 15-0195 prevents from the development and inhibits the progression of rat experimental autoimmune myasthenia gravis. Duplan V; Dutartre P; Druet P; Saoudi A J Neuroimmunol; 2002 Aug; 129(1-2):115-24. PubMed ID: 12161027 [TBL] [Abstract][Full Text] [Related]
2. Suppression of experimental myasthenia gravis by a B-cell epitope-free recombinant acetylcholine receptor. Yi HJ; Chae CS; So JS; Tzartos SJ; Souroujon MC; Fuchs S; Im SH Mol Immunol; 2008 Nov; 46(1):192-201. PubMed ID: 18799218 [TBL] [Abstract][Full Text] [Related]
3. Activation of the adenosine A2A receptor attenuates experimental autoimmune myasthenia gravis severity. Li N; Mu L; Wang J; Zhang J; Xie X; Kong Q; Tang W; Yao X; Liu Y; Wang L; Wang G; Wang D; Jin L; Sun B; Li H Eur J Immunol; 2012 May; 42(5):1140-51. PubMed ID: 22539289 [TBL] [Abstract][Full Text] [Related]
4. Blockade of CD40 ligand suppresses chronic experimental myasthenia gravis by down-regulation of Th1 differentiation and up-regulation of CTLA-4. Im SH; Barchan D; Maiti PK; Fuchs S; Souroujon MC J Immunol; 2001 Jun; 166(11):6893-8. PubMed ID: 11359850 [TBL] [Abstract][Full Text] [Related]
5. Interleukin 10 aggravates experimental autoimmune myasthenia gravis through inducing Th2 and B cell responses to AChR. Zhang GX; Xiao BG; Yu LY; van der Meide PH; Link H J Neuroimmunol; 2001 Feb; 113(1):10-8. PubMed ID: 11137572 [TBL] [Abstract][Full Text] [Related]
6. Protective potential of experimental autoimmune myasthenia gravis in Lewis rats by IL-10-modified dendritic cells. Duan RS; Adikari SB; Huang YM; Link H; Xiao BG Neurobiol Dis; 2004 Jul; 16(2):461-7. PubMed ID: 15193302 [TBL] [Abstract][Full Text] [Related]
7. Role for interferon-gamma in rat strains with different susceptibility to experimental autoimmune myasthenia gravis. Wang HB; Shi FD; Li H; van der Meide PH; Ljunggren HG; Link H Clin Immunol; 2000 May; 95(2):156-62. PubMed ID: 10779409 [TBL] [Abstract][Full Text] [Related]
8. Nasal tolerance in experimental autoimmune myasthenia gravis (EAMG): induction of protective tolerance in primed animals. Shi FD; Bai XF; Li HL; Huang YM; Van der Meide PH; Link H Clin Exp Immunol; 1998 Mar; 111(3):506-12. PubMed ID: 9528890 [TBL] [Abstract][Full Text] [Related]
9. The limitation of IL-10-exposed dendritic cells in the treatment of experimental autoimmune myasthenia gravis and myasthenia gravis. Xiao BG; Duan RS; Zhu WH; Lu CZ Cell Immunol; 2006 Jun; 241(2):95-101. PubMed ID: 17005165 [TBL] [Abstract][Full Text] [Related]
12. Acetylcholine receptor antibody-mediated animal models of myasthenia gravis and the role of complement. Kusner LL; Sengupta M; Kaminski HJ Ann N Y Acad Sci; 2018 Feb; 1413(1):136-142. PubMed ID: 29356015 [TBL] [Abstract][Full Text] [Related]
13. Acetylcholine receptor-induced experimental myasthenia gravis: what have we learned from animal models after three decades? Baggi F; Antozzi C; Toscani C; Cordiglieri C Arch Immunol Ther Exp (Warsz); 2012 Feb; 60(1):19-30. PubMed ID: 22159475 [TBL] [Abstract][Full Text] [Related]
14. Acetylcholine receptor-specific immunosuppressive therapy of experimental autoimmune myasthenia gravis and myasthenia gravis. Luo J; Lindstrom J Ann N Y Acad Sci; 2018 Feb; 1413(1):76-81. PubMed ID: 29377167 [TBL] [Abstract][Full Text] [Related]
15. Pixantrone (BBR2778) reduces the severity of experimental autoimmune myasthenia gravis in Lewis rats. Ubiali F; Nava S; Nessi V; Longhi R; Pezzoni G; Capobianco R; Mantegazza R; Antozzi C; Baggi F J Immunol; 2008 Feb; 180(4):2696-703. PubMed ID: 18250482 [TBL] [Abstract][Full Text] [Related]
16. Induction of peripheral tolerance to experimental autoimmune myasthenia gravis by acetylcholine receptor-pulsed dendritic cells. Xiao BG; Duan RS; Link H; Huang YM Cell Immunol; 2003 May; 223(1):63-9. PubMed ID: 12914759 [TBL] [Abstract][Full Text] [Related]
17. Proteasome inhibition with bortezomib depletes plasma cells and autoantibodies in experimental autoimmune myasthenia gravis. Gomez AM; Vrolix K; MartÃnez-MartÃnez P; Molenaar PC; Phernambucq M; van der Esch E; Duimel H; Verheyen F; Voll RE; Manz RA; De Baets MH; Losen M J Immunol; 2011 Feb; 186(4):2503-13. PubMed ID: 21239719 [TBL] [Abstract][Full Text] [Related]
18. Naturally occurring CD4+CD25+ regulatory T cells prevent but do not improve experimental myasthenia gravis. Nessi V; Nava S; Ruocco C; Toscani C; Mantegazza R; Antozzi C; Baggi F J Immunol; 2010 Nov; 185(9):5656-67. PubMed ID: 20881192 [TBL] [Abstract][Full Text] [Related]